GlassScriptPhysician profile
David M Siegel
NPI 1609864966
$16,049.73
in general payments reported to CMS, 2019-2025
33 companies · $292 in 2025
The $292 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,093 · 2020: $297 · 2021: $4,361 · 2022: $6,819 · 2023: $1,304 · 2024: $883 · 2025: $292.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,459 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,459.06 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $10,692.16 | 2019-2023 | Da Vinci Surgical System |
| Centinel Spine, LLC | $1,211.21 | 2022 | |
| Kerecis Limited | $488.11 | 2024-2025 | Kerecis Omega3 Marigen, Kerecis Surgiclose, Kerecis Omega3 Surgiclose |
| Abbvie INC. | $450.00 | 2019 | |
| Aroa Biosurgery Incorporated | $330.60 | 2023 | |
| Acera Surgical, INC. | $246.88 | 2024 | Restrata Wound Matrix |
| Medtronic, INC. | $201.29 | 2021-2023 | Onyx Frontier |
| Smith+Nephew, INC. | $190.22 | 2020-2023 | Pico 7, Renasys Go V2 Home, Renasys Touch |
| Csl Behring | $181.88 | 2022-2024 | Kcentra |
| Davol INC. | $181.68 | 2019-2025 | Phasix Mesh |
| Kci USA, INC. | $179.11 | 2019-2020 | |
| Integra Lifesciences Corporation | $169.64 | 2022-2023 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Teleflex LLC | $141.40 | 2022 | |
| Ethicon US, LLC | $140.46 | 2021-2023 | Echelon Circular, Echelon Flex, Echelon; Endopath |
| Avanos Medical | $139.91 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urgo Medical North America, LLC | $137.16 | 2023 | Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap, Urgok2 |
| Baxter Healthcare | $116.92 | 2022 | |
| Organogenesis INC. | $115.55 | 2025 | Puraply Wound Matrix |
| Minerva Surgical, INC | $96.70 | 2023 | |
| Sanara Medtech INC. | $83.99 | 2024 | Celleraterx |
| Tela Bio, INC. | $83.40 | 2019-2024 | Ovitex 2s, Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Innocoll Pharmaceuticals Limited | $76.36 | 2022 | |
| Covidien LP | $69.65 | 2019-2020 | |
| Innovation Technologies INC | $68.99 | 2024 | Irrisept |
| Melinta Therapeutics, LLC | $45.10 | 2019 | |
| Convatec INC. | $41.75 | 2024 | |
| Shire North American Group INC | $35.48 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.42 | 2020-2021 | |
| W. L. Gore & Associates, INC. | $30.32 | 2023 | Gore Enform Preperitoneal Biomaterial |
| Mimedx Group, INC. | $23.59 | 2024 | |
| Dilon Technologies, INC. | $17.78 | 2023 | Hemoblast Bellows |
| Becton, Dickinson and Company | $17.30 | 2019 | |
| Baudax Bio INC. | $14.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Siegel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.